Ian Anderson is Honorary Professor of Psychiatry at the University of Manchester, UK and was previously an Honorary Consultant Psychiatrist at Manchester Mental Health and Social Care Trust.
He founded the Manchester Specialist Service for Affective Disorders, a tertiary clinic for complex mood disorders, and was Director until retiring from clinical work in 2011.
His research interests include treatment trials and brain mechanisms in affective disorders. He is co-author of the BAP depression and anxiety disorders treatment guidelines. He chaired the Clinical Guideline Development Group for the NICE (2009) depression treatment guidelines (CG90). He has authored over 130 peer-reviewed papers and edited ‘Fundamentals of Clinical Psychopharmacology’ which won the psychiatry section of the BMA medical book awards 2016.
Elias Dakwar is Assistant Professor of Clinical Psychiatry in the Division on Substance Abuse, Columbia University. After his residency training (University of Chicago Medical Center, 2008), he completed a clinical research fellowship in Addiction Psychiatry (Columbia University, 2011). His research interests include the pharmacological facilitation of mindfulness training with ketamine for alcohol and cocaine misuse. He is currently funded by National Institute on Drug Abuse.
After his PhD in Psychology at Nottingham, Dr Fernie explored the relationships between impulsivity, attentional bias and alcohol consumption in adolescents, at Liverpool until 2010. He moved to work with the late Ian Reid in University of Aberdeen where he ran a Chief Scientist Office-funded randomised controlled trial investigating ketamine as the anaesthetic for electro-convulsive therapy (ECT). He also had a role facilitating research with the Scottish Mental Health Research Network. He is now a clinical Trial Manager at the Centre for Healthcare Randomised Trials (CHaRT) based in the Health Services Research Unit (HSRU) at the University of Aberdeen.
Dan IosifescuDr. Dan Iosifescu is the Director of Clinical Research at the Nathan Kline Institute
and Associate Professor of Psychiatry at the New York University School of Medicine. His research is focused on novel pharmacological treatments (such as ketamine and other glutamatergic drugs) and devices (such as novel forms of magnetic stimulation) for patients with severe mood disorders (major depression and bipolar disorder) and anxiety disorders (PTSD). In his research Dr. Iosifescu uses neuroimaging (MRI, MRS) and neurophysiology (quantitative EEG) techniques to evaluate structural, biochemical, and functional brain abnormalities in mood disorders and their impact on clinical treatment. In parallel Dr. Iosifescu also focuses on the recognition and treatment of cognitive deficits associated with mood disorders.
Colleen Loo is a psychiatrist and Professor at the University of New South Wales in Sydney. She conducted the first randomised controlled trials of TMS, tDCS and ketamine in psychiatry in Australia and has also developed local use of the ultrabrief pulse width ECT. Her group published the first trial of ketamine for resistant depression in the elderly and leads a multicentre, longer duration, trial of ketamine for depression. They have also published a systematic review of the side effects of ketamine, leading to development of the Ketamine Side Effect Tool (KSET).
Rupert McShane is an Associate Professor in the Department of Psychiatry at University of Oxford. A consultant at Oxford Health NHS Foundation trust, he leads a ketamine clinic and the ECT service for Oxfordshire. He is PI on several ketamine related trials and is an advocate of the use of registries and patient completed mood monitoring to complement trial data in the tracking of long term safety and effectiveness of ketamine.
Jerry Sanacora is Professor of Psychiatry; Director, Yale Depression Research Program; Co-Director, Yale New Haven Hospital Interventional Psychiatry Service.
He is part of the Yale group which first identified the antidepressant effect of ketamine. He runs both basic science and clinical laboratories. The former uses a chronic stress model to explore cellular and molecular biology. The latter uses novel MRS and pharmacological challenge paradigms. He leads several early phase trials of novel candidate therapies.
Dr Stone studied medicine at the Royal Free Hospital School of Medicine, London. He trained in Psychiatry at Cambridge and at the Maudsley. He was awarded an MRC Clinical Research Training Fellowship in 2005, and obtained his PhD in 2008. Over the last 10 years, he has worked on brain imaging and glutamatergic neurotransmission, and has completed a number of studies investigating the effect of ketamine on brain function. He is currently working as a Clinical Senior Lecturer with the BRC at the Institute of Psychiatry, King's College London. His main research interests at present are the role of glutamate in psychosis and depression, the early stage testing of novel drug treatments for these conditions, and the development of neuroimaging biomarkers to enable a stratified medicine approach for psychiatric conditions.
Haggai Sharon, MD is a specialist in Internal medicine and Pain Medicine. He is a senior physician and researcher at the Tel Aviv Medical Centre and Tel Aviv University, where he also recently submitted his PhD thesis in Neuroscience. Dr. Sharon's current work combines research into what builds the subjective experience of the self in health and disease. He is especially interested in altered states of consciousness and neuropsychopharmacology, as well as the neurobiology of pain and methods that can rapidly change this aversive experience in a noninvasive, brain-focused and patient-tailored manner. To that aim he combines advanced functional brain imaging, pharmacotherapy and noninvasive brain stimulation and modulation techniques in healthy individuals and in patients.
Dr. Sharon leads the #Consciousness & Psychopharmacolog research team at the TLV-CBF, and is currently a clinical research fellow at Guy’s and St Thomas’ Pain Management and Neuromodulation Centre in London.
John E. Donello, Ph.D. is Vice President of Research Pharmacology and External Science & Innovation at Allergan, LLC. His background spans molecular biology, pharmacology, and translational science within neuroscience, ophthalmology, and dermatology. His specific interest is to identify and develop novel potential therapies and to translate the science into clinical proof of concept for diseases with significant unmet need. He is an inventor of multiple molecules currently undergoing clinical investigation and over 100 issued patents. He received his Ph.D from The Salk Institute of Biological Studies and University of California, San Diego for work in molecular virology. He received a Bachelor of Science, Biology from Indiana University.
Dr. Alison McInnes
graduated from Columbia College of Physicians and Surgeons and completed her
residency at the University of California San Francisco where she received a
Howard Hughes Research Fellowship to study the genetics of mood disorders. She
then ran her own NIMH funded laboratory as an Associate Professor at the Mount
Sinai School of Medicine before returning to the Bay area and founded Kaiser
Permanente’s Regional Ketamine Therapy Program in 2014. As Medical Director of
this program, she convened international conferences for ketamine therapy, a tradition
which will be carried forward in years to come. Given her academic background,
she was delighted to join Actify Neurotherapies network to continue
ketamine-related clinical research and patient care.
- Rupert McShane (Chair)
- Phil Cowen
- Declan McLoughlin
- Celia Morgan
- Gerard Sanacora
- Robert Shoevers